Condition: IgA Nephropathy · Sponsor: Jade Biosciences, Inc.
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
This description comes directly from the study's public registry record.
JADE101 Study Contact · +1 781 201 4703 · JADE101clinicaltrials@jadebiosciences.com
Always discuss trial participation with your own doctor first.
| Jade Clinical Site | Chula Vista, California, United States | Recruiting |
| Jade Clinical Site | Arvada, Colorado, United States | Recruiting |
| Jade Clinical Site | Denver, Colorado, United States | Recruiting |
| Jade Clinical Site | Orlando, Florida, United States | Recruiting |
| Jade Clinical Site | Pembroke Pines, Florida, United States | Recruiting |
| Jade Clinical Site | Houston, Texas, United States | Recruiting |
| Jade Clinical Site | Christchurch, New Zealand | Recruiting |
| Jade Clinical Site | Seoul, South Korea | Recruiting |
| Jade Clinical Site | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07541287